Laddar...
A phase I/II trial of vandetanib for patients with recurrent malignant glioma
Vandetanib is a once-daily multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor–2, epidermal growth factor receptor, and the rearranged-during-transfection oncogene. A phase I trial was conducted to describe the pharmacokinetics of vandetanib in patients with recurr...
Sparad:
| Huvudupphovsmän: | , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Oxford University Press
2012
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3499018/ https://ncbi.nlm.nih.gov/pubmed/23099652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos265 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|